Press releases
- Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
- Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
- Alkermes plc Reports First Quarter 2024 Financial Results
- Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
- Alkermes to Report First Quarter Financial Results on May 1, 2024
- Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
- Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
- Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
More ▼
Key statistics
On Thursday, Alkermes Plc (8AK:FRA) closed at 22.00, 3.77% above its 52-week low of 21.20, set on Nov 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.00 |
---|---|
High | 22.00 |
Low | 22.00 |
Bid | 22.00 |
Offer | 22.60 |
Previous close | 22.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 169.22m |
Free float | 167.11m |
P/E (TTM) | 6.91 |
Market cap | 4.10bn USD |
EPS (TTM) | 3.50 USD |
Data delayed at least 15 minutes, as of May 23 2024 07:23 BST.
More ▼